LD50=65 mg/kg (Orally in mice)
An antipsychotic agent used in schizophrenia. PubChem
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Omalizumab | The therapeutic efficacy of Omalizumab can be decreased when used in combination with Loxapine. |
| Flunisolide | The therapeutic efficacy of Flunisolide can be decreased when used in combination with Loxapine. |
| Ipratropium | The therapeutic efficacy of Ipratropium can be decreased when used in combination with Loxapine. |
| Beclomethasone dipropionate | The therapeutic efficacy of Beclomethasone dipropionate can be decreased when used in combination with Loxapine. |
| Montelukast | The therapeutic efficacy of Montelukast can be decreased when used in combination with Loxapine. |
| Zafirlukast | The therapeutic efficacy of Zafirlukast can be decreased when used in combination with Loxapine. |
| Fluticasone propionate | The therapeutic efficacy of Fluticasone propionate can be decreased when used in combination with Loxapine. |
| Triamcinolone | The therapeutic efficacy of Triamcinolone can be decreased when used in combination with Loxapine. |
| Zileuton | The therapeutic efficacy of Zileuton can be decreased when used in combination with Loxapine. |
| Orciprenaline | The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Loxapine. |
| Terbutaline | The therapeutic efficacy of Terbutaline can be decreased when used in combination with Loxapine. |
| Salmeterol | The therapeutic efficacy of Salmeterol can be decreased when used in combination with Loxapine. |
| Formoterol | The therapeutic efficacy of Formoterol can be decreased when used in combination with Loxapine. |
| Albuterol | The therapeutic efficacy of Salbutamol can be decreased when used in combination with Loxapine. |
| Budesonide | The therapeutic efficacy of Budesonide can be decreased when used in combination with Loxapine. |
| Arformoterol | The therapeutic efficacy of Arformoterol can be decreased when used in combination with Loxapine. |
| Fenoterol | The therapeutic efficacy of Fenoterol can be decreased when used in combination with Loxapine. |
| Pirbuterol | The therapeutic efficacy of Pirbuterol can be decreased when used in combination with Loxapine. |
| Clenbuterol | The therapeutic efficacy of Clenbuterol can be decreased when used in combination with Loxapine. |
| Bambuterol | The therapeutic efficacy of Bambuterol can be decreased when used in combination with Loxapine. |
| Tiotropium | The therapeutic efficacy of Tiotropium can be decreased when used in combination with Loxapine. |
| Ciclesonide | The therapeutic efficacy of Ciclesonide can be decreased when used in combination with Loxapine. |
| Pranlukast | The therapeutic efficacy of Pranlukast can be decreased when used in combination with Loxapine. |
| Roflumilast | The therapeutic efficacy of Roflumilast can be decreased when used in combination with Loxapine. |
| Indacaterol | The therapeutic efficacy of Indacaterol can be decreased when used in combination with Loxapine. |
| Protokylol | The therapeutic efficacy of Protokylol can be decreased when used in combination with Loxapine. |
| Aclidinium | The therapeutic efficacy of Aclidinium can be decreased when used in combination with Loxapine. |
| Fluticasone furoate | The therapeutic efficacy of Fluticasone furoate can be decreased when used in combination with Loxapine. |
| Umeclidinium | The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Loxapine. |
| Olodaterol | The therapeutic efficacy of Olodaterol can be decreased when used in combination with Loxapine. |
| Vilanterol | The therapeutic efficacy of Vilanterol can be decreased when used in combination with Loxapine. |
| Tulobuterol | The therapeutic efficacy of Tulobuterol can be decreased when used in combination with Loxapine. |
| Levosalbutamol | The therapeutic efficacy of Levosalbutamol can be decreased when used in combination with Loxapine. |
| Afatinib | The serum concentration of Afatinib can be increased when it is combined with Loxapine. |
| Bosutinib | The serum concentration of Bosutinib can be increased when it is combined with Loxapine. |
| Brentuximab vedotin | The serum concentration of Brentuximab vedotin can be increased when it is combined with Loxapine. |
| Colchicine | The serum concentration of Colchicine can be increased when it is combined with Loxapine. |
| Edoxaban | The serum concentration of Edoxaban can be increased when it is combined with Loxapine. |
| Ledipasvir | The serum concentration of Ledipasvir can be increased when it is combined with Loxapine. |
| Naloxegol | The serum concentration of Naloxegol can be increased when it is combined with Loxapine. |
| Pazopanib | The serum concentration of Pazopanib can be increased when it is combined with Loxapine. |
| Prucalopride | The serum concentration of Prucalopride can be increased when it is combined with Loxapine. |
| Ranolazine | The serum concentration of Ranolazine can be increased when it is combined with Loxapine. |
| Silodosin | The excretion of Silodosin can be decreased when combined with Loxapine. |
| Topotecan | The serum concentration of Topotecan can be increased when it is combined with Loxapine. |
| Buprenorphine | Loxapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Loxapine. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Loxapine. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Loxapine. |
| Hydrocodone | Loxapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Loxapine. |
| Magnesium sulfate | The therapeutic efficacy of Loxapine can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Loxapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Loxapine may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Loxapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Loxapine. |
| Orphenadrine | Loxapine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Loxapine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Loxapine. |
| Rotigotine | Loxapine may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Loxapine. |
| Sodium oxybate | Loxapine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Loxapine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Loxapine. |
| Thalidomide | Loxapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Loxapine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Lorazepam | The risk or severity of adverse effects can be increased when Loxapine is combined with Lorazepam. |
| Everolimus | The serum concentration of Everolimus can be increased when it is combined with Loxapine. |
| Rifaximin | The serum concentration of Rifaximin can be increased when it is combined with Loxapine. |
| Amisulpride | Loxapine may increase the antipsychotic activities of Amisulpride. |
| Methylphenidate | The risk or severity of adverse effects can be increased when Loxapine is combined with Methylphenidate. |
| Metoclopramide | The risk or severity of adverse effects can be increased when Metoclopramide is combined with Loxapine. |
| Quinagolide | The therapeutic efficacy of Quinagolide can be decreased when used in combination with Loxapine. |
| Sulpiride | Loxapine may increase the antipsychotic activities of Sulpiride. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Loxapine. |
| Lithium citrate | Lithium citrate may increase the neurotoxic activities of Loxapine. |
| Lithium hydroxide | Lithium hydroxide may increase the neurotoxic activities of Loxapine. |
| Mequitazine | Loxapine may increase the arrhythmogenic activities of Mequitazine. |
| Carbamazepine | The serum concentration of the active metabolites of Carbamazepine can be increased when Carbamazepine is used in combination with Loxapine. |
| Linezolid | The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Loxapine. |
| Dicoumarol | The risk or severity of adverse effects can be increased when Loxapine is combined with Dicoumarol. |
| Phenindione | The risk or severity of adverse effects can be increased when Loxapine is combined with Phenindione. |
| Warfarin | The risk or severity of adverse effects can be increased when Loxapine is combined with Warfarin. |
| Phenprocoumon | The risk or severity of adverse effects can be increased when Loxapine is combined with Phenprocoumon. |
| Acenocoumarol | The risk or severity of adverse effects can be increased when Loxapine is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of adverse effects can be increased when Loxapine is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of adverse effects can be increased when Loxapine is combined with Coumarin. |
| (R)-warfarin | The risk or severity of adverse effects can be increased when Loxapine is combined with (R)-warfarin. |
| Ethyl biscoumacetate | The risk or severity of adverse effects can be increased when Loxapine is combined with Ethyl biscoumacetate. |
| Fluindione | The risk or severity of adverse effects can be increased when Loxapine is combined with Fluindione. |
| Clorindione | The risk or severity of adverse effects can be increased when Loxapine is combined with Clorindione. |
| Diphenadione | The risk or severity of adverse effects can be increased when Loxapine is combined with Diphenadione. |
| Tioclomarol | The risk or severity of adverse effects can be increased when Loxapine is combined with Tioclomarol. |
| (S)-Warfarin | The risk or severity of adverse effects can be increased when Loxapine is combined with (S)-Warfarin. |
| Mirtazapine | Loxapine may increase the serotonergic activities of Mirtazapine. |
| Vincristine | The excretion of Vincristine can be decreased when combined with Loxapine. |
| Ethanol | Loxapine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Loxapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Loxapine. |
| Zimelidine | The risk or severity of adverse effects can be increased when Loxapine is combined with Zimelidine. |